WO1997025033A1 - Antithrombotic diamines - Google Patents

Antithrombotic diamines Download PDF

Info

Publication number
WO1997025033A1
WO1997025033A1 PCT/US1996/017995 US9617995W WO9725033A1 WO 1997025033 A1 WO1997025033 A1 WO 1997025033A1 US 9617995 W US9617995 W US 9617995W WO 9725033 A1 WO9725033 A1 WO 9725033A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
alkyl
divalent radical
Prior art date
Application number
PCT/US1996/017995
Other languages
English (en)
French (fr)
Inventor
Jolie A. Bastian
Nickolay Y. Chirgadze
Michael L. Denney
Robert J. Foglesong
Richard W. Harper
Mary G. Johnson
Valentine J. Klimkowski
Todd J. Kohn
Ho-Shen Lin
Michael P. Lynch
Jefferson R. Mccowan
Alan D. Palkowitz
Michael E. Richett
Daniel J. Sall
Gerald F. Smith
Kumiko Takeuchi
Jennifer M. Tinsley
Minsheng Zhang
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to AT96940354T priority Critical patent/ATE284690T1/de
Priority to DE69634045T priority patent/DE69634045T2/de
Priority to JP52518397A priority patent/JP2002500618A/ja
Priority to EP96940354A priority patent/EP0863755B1/en
Priority to AU77255/96A priority patent/AU7725596A/en
Publication of WO1997025033A1 publication Critical patent/WO1997025033A1/en
Priority to US09/369,416 priority patent/US6265575B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention relates to thrombin inhibitors which are useful anticoagulants in mammals.
  • diamine derivatives having high anticoagulant activity, and antithrombotic activity.
  • this invention relates to new inhibitors of thrombin, pharmaceutical 0 compositions containing the compounds as active ingredients, and the use of the compounds as anticoagulants for prophylaxis and treatment of thromboembolic disorders such as venous thrombosis, pulmonary embolism, arterial thrombosis, in particular myocardial ischemia, yocardial infarction and B cerebral thrombosis, general hypercoagulable states and local hypercoagulable states, such as following angioplasty and coronary bypass operations, and generalized tissue injury as it relates to the inflammatory process.
  • the diamine derivatives are useful as anticoagulants in in vi tro 0 applications.
  • thrombosis The process of blood coagulation, thrombosis, is triggered by a complex proteolytic cascade leading to the formation of thrombin.
  • Anticoagulation currently is achieved by the administration of heparins and coumarins.
  • Parenteral pharmacological control of coagulation and thrombosis is 0 based on inhibition of thrombin through the use of heparins.
  • Heparins act indirectly on thrombin by accelerating the inhibitory effect of endogenous antithrombin III (the main physiological inhibitor of thrombin) . Because antithrombin III levels vary in plasma and because clot-bound thrombin seems resistant to this indirect mechanism, heparins can be an ineffective treatment.
  • coagulation assays are believed to be associated with efficacy and with safety, heparin levels must be monitored with coagulation assays (particularly the activated partial thromboplastin time (APTT) assay) .
  • APTT activated partial thromboplastin time
  • Coumarins impede the generation of thrombin by blocking the posttranslational gamma-carboxylation in the synthesis of prothrombin and other proteins of this type. Because of their mechanism of action, the effect of coumarins can only develop slowly, 6-24 hours after administration. Further, they are not selective anticoagulants.
  • Coumarins also require monitoring with coagulation assays (particularly the prothrombin time (PT) assay) .
  • heparins and coumarins are effective anticoagulants, no commercial drug has yet emerged from the small synthetic molecules; and despite the continuing promise for this class of compounds, there still exists a need for anticoagulants which act selectively on thrombin, and which, independent of antithrombin III, exert inhibitory action shortly after administration, preferably by an oral route, and do not interfere with lysis of blood clots, as required to maintain hemostasis.
  • the present invention is directed to the discovery that the compounds of the present invention, as defined below, are potent thrombin inhibitors that may have high bioavailability following oral administration. According to the invention there is provided a method of inhibiting thrombin comprising using an effective amount of a thrombin inhibiting compound of formula I (or a pharmaceutically acceptable salt thereof)
  • A- is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens in which the valences are in the 1,4- or 2,5- or 3,6- relationship, and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which the valences are in the
  • A- is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens in which the valences are in the 1,4- or 2,5- or
  • X 1 is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 2 is imino, a direct bond, methylene, 0 or S; j is 0; k is 0; m is 1, 2, 3 or 4; provided that when m is 1, then X 2 is a direct bond; and
  • R a and R-° are independently hydrogen or (1-3C)alkyl or the group NR a R*° is 2- (hydroxymethyl) -1-pyrrolidinyl, 2- (methoxymethyl) - 1-pyrrolidinyl, pyrrolidino, piperidino, 2-methyl- 1-piperidinyl, morpholino or hexamethyleneimino; or
  • X 2 is imino, 0 or S; j is 1; k is 1; m is 1; R 2 is hydroxy; and R a and R*° are independently hydrogen or (1-3C)alkyl or the group NR a R-b is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
  • X 2 is imino, 0 or S; j is 1; k is 1; m is 0; R 2 is hydroxymethyl or methoxycarbonyl; and R a and R*° are independently hydrogen or (1-3C)alkyl; or
  • X 2 is imino, 0 or S; j is 0, 1, 2 or 3 ; k is 1,- rn is 0 or 1; provided that j and m are not both 0; R 2 and R a together form a diradical -(CH2) n ⁇ in which n is 2, 3 or 4 and the sum of m and n is 3 or 4; and R-° is hydrogen or (1-3C) alkyl; or
  • X 2 is -NH-C(O)-; j is 0; k is 0; m is 1; and R a and R-° are independently hydrogen or (1-3C)alkyl or the group NR a R*° is pyrrolidino, piperidin
  • X- 3 is a direct bond, methylene, imino, 0 or S; q is 0, 1 or 2 ,* and r is 0 or 1; provided that q and r are not both zero, and provided that when q is 1 and r is 0, then X*-* is a direct bond; each R3 is hydrogen or the two R- 3 groups together form a divalent radical -(CH2)s _ in which s is 3 or 4; and R c and R ⁇ are independently hydrogen or (1-4C)alkyl or the group NR C R ⁇ is 2- (hydroxymethyl) -1-pyrrolidinyl,
  • ⁇ 3 is imino, 0 or S; q is 0; r is 1; one R 3 group is (1-5C) alkyl and the other R3 group is independently hydrogen or (1-5C) alkyl; and R c and R°- are independently hydrogen or (1-3C) alkyl or the group NR C R ⁇ is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
  • X 3 is imino, 0 or S; q is 0, 1 or 2 ; r is 1; one R 3 group is hydrogen and the other R 3 group together with the group R c forms a divalent radical -(CH2)t- in which t is 2, 3 or 4 such that the resulting ring is a pyrrolidine or piperidine; and R ⁇ is hydrogen or (1-3C)alkyl; or
  • X 3 is -N(R h )-; q is 0; r is 1; the R 3 group on the carbon bonded to X 3 and the group R* 1 together form a diradical -(CH2)3 ⁇ ; the other R 3 group is hydrogen; and R c and R* are independently (1-3C)alkyl or the group NR c R d is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
  • X 3 is ethene-1, 2-diyl or ethyne-l,2-diyl; q is 1; r is 0; and R c and R ⁇ are independently (1-3C)alkyl or the group NR C R" is pyrrolidino, piperidino, morpholino or hexamethyleneimino.
  • One particular method of inhibiting thrombin comprises using an effective amount of a thrombin inhibiting compound of formula I, or a pharmaceutically acceptable salt thereof, wherein
  • a 2 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6- relationship and which divalent radical may bear a methyl, hydroxy or methoxy substituent (and more particularly, which divalent radical does not bear a substituent) ;
  • a 3 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6- relationship and which divalent radical may bear a (1-3C)alkyl, (1-2C) alkoxy or halo substituent (and more particularly, which divalent radical may bear a (1-3C)alkyl or halo substituent);
  • R-*- denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl;
  • X 1 is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 2 is a direct bond, methylene, O or S;
  • j and k are both 0;
  • m is 1, 2, 3 or 4; provided that when is 1, then X 2 is a direct bond;
  • R a and R-° are independently hydrogen or (1-3C)alkyl or the group NR a R-° is pyrrolidino, piperidino, morpholino or hexamethyleneimino;
  • X 3 is a direct bond, methylene, imino, O or S;
  • q is
  • each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s ⁇ in which s is 3 or 4; and R c and R°- are independently (1-3C)alkyl or the group NR c Rcl i s pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl.
  • a compound of formula I in which j and k are both 0 may be denoted as a compound of formula I ' . (CH 2 ) q - (CHR 3 -CHR 3 ) r -NR c R d
  • a 2 is para-phenylene which may bear a substituent R3 ortho to the group X 2 and R is methyl, hydroxy or methoxy or A 2 is pyridine-2, 5-diyl in which the 2-position is joined to X 2 (and more particularly, which divalent radical does not bear a substituent) ;
  • a 3 is para-phenylene which may bear a substituent R e ortho to the group X 3 and R e is (1-3)alkyl, (1-2C)alkoxy or halo or
  • a 3 is pyridine-2, 5-diyl in which the 2-position is joined to X 3 ⁇ and more particularly, R e is (i_3) a ⁇ ky ⁇ D r halo) ;
  • Ri denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl; xi is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 2 is a direct bond, methylene, 0 or S; j and k are both 0; m is 1, 2, 3 or 4; provided that when m is 1, then X 2 is a direct bond; and R a and R*° are independently hydrogen or (1-3C)alkyl or the group NR a R D is pyrrolidino, piperidino or morpholino;
  • X 3 is a direct bond, methylene, imino, 0 or S; q is 0, 1 or 2,* and r is 0 or 1; provided that q and r are not both zero, and provided that when q is 1 and r is 0, then X 3 is a direct bond; each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s ⁇ in which s is 3 or 4; and R c and R d are independently (1-3C)alkyl or the group NR c R d is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl.
  • a more particular aspect of any of the above methods is one wherein said compound is a compound of formula Ia
  • D is CH, CR3 or N in which R3 is methyl, hydroxy or methoxy (and more particularly D is CH or N)
  • E is CH, CR e or N in which R e is (1-3C)alkyl, (1-2C)alkoxy or halo (and more particularly E is CH, CR e or N in which R e is (l-3C)alkyl or halo)
  • R e is (1-3C)alkyl, (1-2C)alkoxy or halo
  • R 5 is hydrogen, halo, methyl, hydroxy or methoxy,* R ⁇ is hydrogen, hydroxy or methoxy;
  • X 1 is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 2a is methylene or 0; and
  • R a and R-° are independently hydrogen or (1-3C)alkyl or the group NR a R-° is pyrrolidino or piperidino;
  • X 3a is methylene, imino, 0 or S; and each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s- i which s is 3 or 4;
  • R c and R d are independently (1-3C)alkyl or the group NR c R d is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl.
  • a particular method in which said compound is one of formula Ia is wherein A is S; D is CH; E is CR e in which R e is methoxy; R ⁇ is hydrogen; R& is hydroxy; X-*- is methylene; X 2a is O; and the group NR a R*° is pyrrolidino; X 3a is 0; and the two R 3 groups together form a divalent radical ⁇ (CH2)s _ in which s is 4 and which forms a trans-1,2- cyclohexanediyl group; and R c and R d are each methyl or the group NR c R d is pyrrolidino.
  • a compound of formula Ia also may be expressed as a compound of formula I or as a compound of formula I ' .
  • G is CH, CR k or N in which R is methyl, hydroxy or methoxy;
  • M is CH, CR or N in which R m is (1-3C) alkyl, (1-2C)alkoxy or halo; R ⁇ is hydrogen, halo, methyl, hydroxy or methoxy;
  • R6 is hydrogen, hydroxy or methoxy
  • X 1 is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 2 -° is a direct bond or O; and R a and R-° are independently hydrogen or (1-3C)alkyl or the group NR a R ⁇ is pyrrolidino or piperidino; and
  • R c and R d are independently (1-3C) alkyl or the group NR c R d is 2- (hydroxymethyl) -1-pyrrolidinyl, 2- (methoxymethyl) -1-pyrrolidinyl, pyrrolidino, piperidino or morpholino.
  • a more particular method in which said compound is one of formula lb is wherein A is S; G is CH or N; M is CH, CR m or N in which R m is methyl, methoxy, chloro or bromo; R 5 is hydrogen; R ⁇ is hydroxy; X-*- is methylene; X 2 -° is a direct bond or 0; the group R a R ⁇ is pyrrolidino; and R c and R d are each methyl or the group NR c R d is 2- (hydroxymethyl) -
  • a further particular aspect of any of the above methods is one wherein said compound is one in which X-*- is methylene.
  • a further particular aspect of any of the above methods is one wherein said compound is one in which s is 4.
  • Another particular aspect of any of the above methods is one wherein said compound is one in which A is S.
  • a further particular aspect of any of the above methods is one wherein said compound is a compound of formula I in which Rl denotes a hydroxy substituent at the position corresponding to the 6-position of a benzo[J ] thiophene or a compound of formula Ia or of formula lb in which R ⁇ is hydrogen and R ⁇ is hydroxy.
  • a selected aspect of the above methods is one in which said compound is a compound of formula la in which A is S, D is CH or N, E is CH or N, R 5 is hydrogen, R 6 is hydroxy, the group -X 2a - (CH2)2 ⁇ NR a R b is 2- (1-pyrrolidinyl)ethoxy, and the group -X 3a -CHR 3 -CHR 3 -NR c R d is 3- (1-pyrrolidinyl)propyl
  • a preferred method of the invention includes one wherein said compound of formula I is one of those described herein at Examples 123, 124 and 164.
  • the present invention also provides a method of inhibiting coagulation in a mammal comprising administering to a mammal in need of treatment, a coagulation inhibiting dose of a thrombin inhibiting compound of formula I having any of the above definitions.
  • the present invention further provides a method of inhibiting thrombin comprising administering to a mammal in need of treatment, a thrombin inhibiting dose of a thrombin inhibiting compound of formula I having any of the above definitions.
  • the present invention provides a method of treating a thromboembolic disorder comprising administering to a mammal in need of treatment, an effective dose of a thrombin inhibiting compound of formula I having any of the above definitions.
  • thrombin inhibiting compound of formula I having any of the above definitions for the manufacture of a medicament for treatment of a thromboembolic disorders.
  • a prodrug (or a pharmaceutically acceptable salt thereof) of any of the above described thrombin inhibiting compounds of formula I which will form a prodrug.
  • a compound of formula I (or formula Ia or formula lb) which will form a prodrug includes one in which Ri (or R5 or R ⁇ ) or a substituent on A 2 or A 3 is hydroxy, carbamoyl, aminomethyl or hydroxymethyl, or one in which one or both of R a and R*° is hydrogen or the group NR a R*° includes a hydroxymethyl group, or one in which R 2 is hydroxy, or one in which one or both of R c and R d is hydrogen or the group NR c R d includes a hydroxymethyl group.
  • Particular compounds of formula I which will form a prodrug include those in which R (or R ⁇ or R ⁇ ) is hydroxy, carbamoyl, aminomethyl or hydroxymethyl or in which one or both of R a and R D is hydrogen. (It will be recognized that a thrombin inhibiting compound of formula I also may serve as a prodrug for a different thrombin inhibiting compound of formula I) .
  • a pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier, diluent or excipient, a prodrug of a thrombin inhibiting compound of formula I (or of a pharmaceutically acceptable salt thereof) as provided in any of the above descriptions.
  • a 2 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens in which the valences are in the 1,4- or 2,5- or 3,6- relationship, and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which the valences are in the
  • a 3 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens in which the valences are in the 1,4-' or 2,5- or
  • Ri denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl; x is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 2 is imino, a direct bond, methylene, 0 or S; j is 0; k is 0; is 1, 2, 3 or 4; provided that when m is 1, then X 2 is a direct bond; and R a and R-° are independently hydrogen or (1-3C) alkyl or the group NR a R-° is 2- (hydroxymethyl) -1-pyrrolidinyl, 2- (methoxymethyl) - 1-pyrrolidinyl, pyrrolidino, piperidino, 2-methyl- 1-piperidinyl, morpholino or hexamethyleneimino; or
  • X 2 is imino, 0 or S; j is 1; k is 1; m is 1; R 2 is hydroxy,* and R a and R * ° are independently hydrogen or (1-3C) alkyl or the group NR a R-° is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or (c) X 2 is imino, 0 or S; j is 1; k is 1; m is 0; R 2 is hydroxymethyl or methoxycarbonyl; and R a and R-° are independently hydrogen or (1-3C)alkyl; or
  • X 2 is imino, 0 or S; j is 0, 1, 2 or 3 ; k is 1; m is 0 or 1; provided that j and m are not both 0; R 2 and R a together form a diradical -(CH2) n ⁇ i which n is 2, 3 or 4 and the sum of m and n is 3 or ; and R-° is hydrogen or (1-3C) alkyl; or
  • X 2 is -NH-C(O)-; j is 0; k is 0; m is 1; and R a and R-° are independently hydrogen or (1-3C)alkyl or the group
  • NR a R-° is pyrrolidino, piperidino, morpholino or hexamethy1eneimino
  • X 3 is a direct bond, methylene, imino, 0 or S; q is 0, 1 or 2; and r is 0 or 1; provided that q and r are not both zero, and provided that when q is 1 and r is 0, then X 3 is a direct bond; each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s _ i which s is 3 or 4; and R c and R d are independently hydrogen or (1-4C) alkyl or the group NR c R d is 2- (hydroxymethyl) -1-pyrrolidinyl, 2- (methoxymethyl) -1-pyrrolidinyl, pyrrolidino, piperidino, morpholino, hexamethyleneimino, 1-imidazolyl or 4,5-dihydro- 1-imidazolyl; or
  • X 3 is imino, 0 or S; q is 0; r is 1; one R 3 group is (1-5C)alkyl and the other R 3 group is independently hydrogen or (1-5C) alkyl; and R c and R d are independently hydrogen or (1-3C)alkyl or the group NR c R d is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
  • X 3 is imino, 0 or S; q is 0, 1 or 2,* r is 1; one R 3 group is hydrogen and the other R 3 group together with the group R c forms a divalent radical - ⁇ CH2)t ⁇ in which t is 2, 3 or 4 such that the resulting ring is a pyrrolidine or piperidine; and R d is hydrogen or (1-3C) alkyl; or
  • X 3 is -N(R h )-; q is 0; r is 1; the R 3 group on the carbon bonded to X 3 and the group R h together form a diradical -(CH 2 )3-; the other R 3 group is hydrogen; and R c and R d are independently (1-3C)alkyl or the group NR c R is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
  • X 3 is ethene-l,2-diyl or ethyne-l,2-diyl; q is 1; r is 0; and R c and R d are independently (1-3C)alkyl or the group NR c R is pyrrolidino, piperidino, morpholino or hexamethyleneimino; provided that the compound is not one in which A is S; A 2 is para-phenylene; A 3 is para-phenylene; R denotes zero substituents on the benz-ring or R 1 denotes a hydroxy or methoxy substituent at the 6-position of the benzo [Jb] thiophene ring; X-*- is carbonyl; X 2 is 0; j and k are both 0, the group -(CH2)m _ is ethylene; R a and R-° are independently (1-3C)alkyl or the group NR a R-° is pyrrolidino, piperidin
  • a 2 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6- relationship and which divalent radical may bear a methyl, hydroxy or methoxy substituent (and more particularly, which divalent radical does not bear a substituent) ;
  • a 3 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6- relationship and which divalent radical may bear a (1-3C)alkyl, (1-2C)alkoxy or halo substituent (and more particularly, which divalent radical may bear a (l-3C)alkyl or halo substituent) ;
  • R 1 denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl;
  • x is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 3 is a direct bond, methylene, imino, O or S; q is 0, 1 or 2; and r is 0 or 1; provided that q and r are not both zero, and provided that when q is 1 and r is 0, then X 3 is a direct bond; each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s ⁇ in which s is 3 or 4; and R c and R are independently (1-3C)alkyl or the group NR c R d is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl.
  • a particular novel compound of formula I as described above is one in which
  • a 2 is para-phenylene which may bear a substituent
  • R3 ortho to the group X 2 and RJ is methyl, hydroxy or methoxy or
  • a 2 is pyridine-2, 5-diyl in which the 2-position is joined to X 2 (and more particularly, which divalent radical does not bear a substituent) ;
  • a 3 is para-phenylene which may bear a substituent
  • R e ortho to the group X 3 and R e is (1-3)alkyl, (1-2C)alkoxy or halo or
  • a 3 is pyridine-2, 5-diyl in which the 2-position is joined to X 3 ⁇ and more particularly, R e is (i_3) a i yl or halo)
  • R denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl;
  • X 1 is 0, S, methylene, carbonyl or ethene-1, 1-diyl
  • X 2 is a direct bond, methylene, 0 or S
  • j and k are both 0
  • m is 1, 2, 3 or 4
  • R a and R*° are independently hydrogen or (1-3C)alkyl or the group NR a R-° is pyrrolidino, piperidino or morpholino
  • X 3 is a direct bond, methylene, imino, 0 or S
  • q is
  • each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s _ i which s is 3 or 4; and R c and R are independently (1-3C)alkyl or the group R c R is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl .
  • a more particular novel compound of the invention is a compound of formula Ia
  • D is CH, CR3 or N in which R3 is methyl, hydroxy or methoxy (and more particularly D is CH or N) ;
  • E is CH, CR e or N in which R e is (1-3C)alkyl,
  • R5 is hydrogen, halo, methyl, hydroxy or methoxy
  • R ⁇ is hydrogen, hydroxy or methoxy
  • X 1 is O, S, methylene, carbonyl or ethene-1, 1-diyl
  • X 2a is methylene or 0
  • R a and R-° are independently hydrogen or (1-3C)alkyl or the group R a R-° is pyrrolidino or piperidino;
  • X 3a is methylene, imino, O or S; and each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s- i which s is 3 or 4; and R c and R are independently (1-3C)alkyl or the group R c R d is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl; provided that the compound is not one in which A is S; D is CH; E is CH; R 5 is hydrogen, R 6 is hydrogen, hydroxy or methoxy; ⁇ l is carbonyl; X 2a is O; R a and R-° are independently (1-3C)alkyl or the group NR a Rb is pyrrolidino or piperidino; X 3a is O; each R 3 is hydrogen; and R c and R d are independently (1-3C)alkyl or the group NR c R is pyrrolidino, piperidino,
  • a particular novel compound of formula Ia is one wherein A is S; D is CH; E is CR e in which R e is methoxy; R5 is hydrogen; R- > is hydroxy; X 1 is methylene; X 2a is 0; and the group NR R-° is pyrrolidino; X 3a is 0; and the two R 3 groups together form a divalent radical -(CH2)s ⁇ i which s is 4 and which forms a trans-1,2-cyclohexanediyl group; and R c and R d are each methyl or the group R c R d is pyrrolidino.
  • An additional particular novel compound of formula I is one which may be denoted as a compound of formula lb
  • G is CH, CR or N in which R is methyl, hydroxy or methoxy; M is CH, CR m or N in which R m is (1-3C)alkyl,
  • R 5 is hydrogen, halo, methyl, hydroxy or methoxy
  • R& is hydrogen, hydroxy or methoxy; x is 0, S, methylene, carbonyl or ethene-1, 1-diyl;
  • X 2t) is a direct bond or 0; and R a and R-° are independently hydrogen or (1-3C)alkyl or the group NR a Rb is pyrrolidino or piperidino; and
  • R c and R are independently (1-3C)alkyl or the group NR c R d is 2- (hydroxymethyl) -1-pyrrolidinyl, 2- (methoxymethyl) -1-pyrrolidinyl, pyrrolidino, piperidino or morpholino.
  • a more particular novel compound is one of formula lb is wherein A is S; G is CH or N; M is CH, CR or N in which R m is methyl, methoxy, chloro or bromo,* R5 is hydrogen; R ⁇ is hydroxy; x is methylene; X 2 - 0 is a direct bond or 0; the group NR a R-° is pyrrolidino; and R c and R are each methyl or the group NR c R d is 2- (hydroxymethyl) -1-pyrrolidinyl, 2- (methoxymethyl) -1-pyrrolidinyl, pyrrolidino or morpholino.
  • a further particular novel compound of the invention is any of the above novel compounds wherein ⁇ l is methylene.
  • a further particular novel compound of the invention is any of the above novel compounds wherein s is 4.
  • A is S.
  • a further particular novel compound of the invention is any of the above novel compounds wherein said compound is a compound of formula I in which R denotes a hydroxy substituent at the position corresponding to the 6-position of a benzo [b] thiophene or a compound of formula Ia or of formula lb in which R ⁇ is hydrogen and R ⁇ is hydroxy.
  • a selected novel compound of the above novel compounds is a compound of formula Ia in which A is S, D is CH or N, E is CH or N, R ⁇ is hydrogen, R ⁇ is hydroxy, the group -X 2a -(CH2) 2"NR a R b is 2- (1-pyrrolidinyl) ethoxy, and the group -X 3a -CHR 3 -CHR 3 -NR c R d is 3- (1-pyrrolidinyl)propyl, 2- (1-pyrrolidinyl)ethoxy, trans-2- (1-pyrrolidinyl) - cyclohexyloxy or trans-2- (1-piperidyl)cyclohexyloxy.
  • a preferred novel compound of the invention includes one wherein said compound of formula I is one of those described herein at Examples 123, 124 and 164.
  • a pharmaceutically acceptable salt of an antithrombotic diamine of the instant invention includes one which is an acid-addition salt made with an acid which provides a pharmaceutically acceptable anion.
  • an acid additon salt of a novel compound of formula I as provided above made with an acid which affords a pharmaceutically acceptable anion provides a particular aspect of the invention. Examples of such acids are provided hereinbelow.
  • a pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier, diluent or excipient, a novel compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in any of the above descriptions.
  • Halo is fluoro, chloro, bromo or iodo.
  • Alkyl, alkoxy, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl” embraces only the straight chain ("normal") radical, a branched chain isomer such as "isopropyl” being specifically denoted.
  • the present invention encompasses a compound of formula I as a mixture of diastereomers, as well as in the form of an individual diastereomer, and that the present invention encompasses a compound of formula I as a mixture of enantiomers, as well as in the form of an individual enantiomer, any of which mixtures or form possesses inhibitory properties against thrombin, it being well known in the art how to prepare or isolate particular forms and how to determine inhibitory properties against thrombin by standard tests including those described below.
  • a compound of formula I (or salt or prodrug, etc.) may exhibit polymorphism or may form a solvate with water or an organic solvent.
  • the present invention also encompasses any such polymorphic form, any solvate or any mixture thereof. Particular values are listed below for radicals, substituents, and ranges, for illustration only, and they do not exclude other defined values or other values within defined ranges for the radicals and substituents.
  • a particular value for a (1-2C) lkyl group is methyl or ethyl; for a (1-3C)alkyl group is methyl, ethyl, propyl or isopropyl; for a (l-4C)alkyl group is methyl, ethyl, propyl, isopropyl or butyl; for a (1-5C)alkyl group is methyl, ethyl, propyl, isopropyl, butyl or pentyl; and for a (1-2C)alkoxy group is methoxy or ethoxy.
  • 6-membered ring heteroaromatic divalent radical is pyridin- 2, 5-diyl, pyridazin-3, 6-diyl, pyrazin-2, 5-diyl, or pyrimidin- 2, 5-diyl (and more particularly, pyridin-2, 5-diyl or pyrazin- 2, 5-diyl; especially pyridin-2, 5-diyl) .
  • a particular value for A 2 or A 3 when it is a 5-membered ring heteroaromatic divalent radical is furan-2, 5-diyl, thiophen-2, 5-diyl, oxazol-2, 5-diyl, thiazol-2, 5-diyl, isoxazol-3 , 5-diyl, isothiazol-3 , 5-diyl, 1, 3,4-oxadiazol-2, 5-diyl or 1,3,4- thiadiazol-2, 5-diyl (and more particularly, isoxazol- 3, 5-diyl) .
  • a compound of formula I may be made by processes which include processes known in the chemical art for the production of known compounds of formula I or of structurally analogous compounds or by a novel process described herein.
  • a process for a novel compound of formula I (or a pharmaceutically acceptable salt thereof) , novel processes for a compound of formula I and novel intermediates for the manufacture of a compound of formula I as defined above provide further features of the invention and are illustrated by the following procedures in which the meanings of the generic radicals are as defined above, unless otherwise specified. It will be recognized that it may be preferred or necessary to prepare a compound of formula I in which a functional group is protected using a conventional protecting group, then to remove the protecting group to provide the compound of formula I .
  • a process for preparing a novel compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in any of the above descriptions which is selected from:
  • the reductive removal conveniently is carried out using sodium borohydride in trifluoroacetic acid in a manner similar to that described in Example 2, Part D, or using triethylsilane in trifluroracetic acid in a manner similar to that described in Example 3, Part E.
  • An intermediate alcohol of formula II (or formula Ila or formula lib) provides an additional feature of the invention; it may be obtained by reducing the carbonyl group of a corresponding ketone of formula I (or formula Ia or formula lb) in which ⁇ l is carbonyl, for example by using lithium aluminium hydride in tetrahydrofuran in a manner similar to that described in Example 2, Part D, or Example 3, Part E or by using diisobutylaluminium hydride in tetrahydrofuran in a manner similar to that described in Example 32, Part A.
  • L denotes a leaving group. It may be preferred to generate the leaving group of the compound of formula XII in si tu from the corresponding hydroxy compound and perform the alkylation under Mitsunobu conditions using triphenyl ⁇ phosphine and diethyl azodicarboxylate in an inert solvent, for example, as described in Example 4, Part B for the preparation of an intermediate compound.
  • a compound of formula XII in which L is chloro, bromo, iodo or a sulfonate, such as methanesulfonate or p-toluenesulfonate may be used, preferably in conjunction with a base such as cesium carbonate, using a similar procedure to that described in Example 3, Part D, for example as described in Example 5, Part C.
  • L denotes a leaving group as defined above. It may be preferred to generate the leaving group of the compound of formula XIV from the corresponding hydroxy compound and to perform the alkyiation under Mitsunobu conditions as described above. Alternatively, L may have any of the values described above for L, and the alkyiation may be carried out using a similar procedure to that described in Example 3, Part D.
  • reaction is conveniently carried out with a compound of formula XVI in which L is chloro and the sodium alkoxide derived from an alcohol of formula XVII using conditions described in Example 9, Part B and further illustrated in Example 33, Part B.
  • condensation conveniently is carried out in an inert solvent such as tetrahydrofuran at about 0 °C, for example as described in Example 34, Part B.
  • the substitution reaction is carried out by heating the reagents XXVIII and XXIX in dimethylformamide or tetrahydrofuran using sodium hydride or potassium carbonate, for example as illustrated in Example 59, Part B; in Example 121, Part B; in Example 145, Part C; in Example 147 or in Example 117, Part D for the preparation of an intermediate of formula XXV.
  • a substituent on A 3 is amino
  • reduction of a corresponding compound of formula I in which a substituent on A 3 is nitro The reduction may be carried out using a conventional method, for example by catalytic hydrogenation as described in Example 97.
  • the activated derivative is the acid anhydride or the acid chloride, and the substitution is carried out in a polar solvent, for example as in Example 111 or Example 113.
  • a polar solvent for example as in Example 111 or Example 113.
  • (Z) For a compound of formula I in which a substituent on A 3 is - HCH 2 R f or a compound of formula I in which -(CH 2 ) j -(CHR 2 ) k -(CH2)m-NR a R b terminates in -CH 2 -NR a R b - reduction of the amide of a corresponding compound of formula I in which a substituent on A 3 is -NHC(0)R f or of an intermediate compound corresponding to a compound of formula I but in which -(CH 2 ) j -(CHR 2 ) -(CH2)m-NR a R b terminates in -C(0)NR a R b .
  • the reduction conveniently is carried out using lithium aluminum
  • a pharmaceutically acceptable salt of a compound of formula I when required, it may be obtained by reacting the basic form of such a compound of formula I with an acid affording a physiologically acceptable counterion or by any other conventional procedure.
  • a 2 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6- relationship;
  • a 3 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6- relationship and which divalent radical may bear a (1-3C)alkyl or halo substituent; Ri denotes 0, 1 or 2 substituent
  • X 1 is 0, S, methylene, carbonyl or ethene-1, 1-diyl
  • X 2 is a direct bond, methylene, 0 or S
  • j and k are both 0
  • m is 1, 2, 3 or 4
  • R a and R b are independently hydrogen or (1-3C)alkyl or the group NR a R b is pyrrolidino, piperidino, morpholino or hexamethyleneimino
  • X 3 is a direct bond, methylene, imino, 0 or S
  • q is
  • each R 3 is hydrogen or the two R 3 groups together form a divalent radical -(CH2)s ⁇ i which s is 3 or 4; and R c and R d are independently (1-3C)alkyl or the group NR c R d is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl; provided that the compound is not one in which A is S; A 2 is para-phenylene; A 3 is para-phenylene; R denotes zero substituents on the benz-ring or R denotes a hydroxy or methoxy substituent at the 6-position of the benzo [b] thiophene ring; x is carbonyl; X 2 is 0; the group -(CH2) ⁇ r is ethylene; R and R and R
  • a compound corresponding to a compound of formula I but in which a functional group is protected may serve as an intermediate for a compound of formula I. Accordingly, such protected intermediates for a novel compound of formula I provide further aspects of the invention.
  • Phenol protecting groups are well known in the art, for example as described in T.W. Greene and P.G.M. Wuts, "Protecting Groups in Organic Synthesis" (1991) .
  • RP particularly values include, for example, benzyl (for example as described in Example 41 or Example 81) and allyl (for example as described in Example 88) .
  • RP may denote a functionalized resin, for example as disclosed in H.V. Meyers, et al. , Molecular Diversity, (1995), 1, 13-20.
  • the invention includes pharmaceutically acceptable salts of the thrombin inhibiting compounds defined by the above formula I.
  • a particular diamine of this invention possesses one or more sufficiently basic functional groups to react with any of a number of inorganic and organic acids affording a physiologically acceptable counterion to form a pharmaceutically acceptable salt.
  • Acids commonly employed to form pharmaceutically acceptable acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p .
  • salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1, 4-dioate, hexyne-1, 6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbut
  • the necessary starting materials for the preparation of a compound of formula I may be prepared by procedures which are selected from standard techniques of organic chemistry, including aromatic and heteroaromatic substitution and transformation, from techniques which are analogous to the syntheses of known, structurally similar compounds, and techniques which are analogous to the above described procedures or procedures described in the Examples. It will be clear to one skilled in the art that a variety of sequences is available for the preparation of the starting materials. Starting materials which are novel provide another aspect of the invention.
  • an intermediate alcohol of formula II may be obtained by reduction of a corresponding ketone of formula I.
  • an alcohol of formula II may be obtained by condensation of an organolithium compound of formula IX with a corresponding aldehyde of formula XX
  • An intermediate of formula III may be prepared by any of a number of known procedures.
  • a preferred method for a compound of formula III in which A is S, particularly when j and k are both 0, is the cross coupling of a boronic acid of formula XXII
  • X is, for example, bromo, iodo or trifluoromethane- sulfonate, for example as described in Examples 1, 2, 4 and 16.
  • a preferred method is a copper mediated cross coupling of a compound of formula XXIII and a 2-metalated benzofuran, such as described in Example 119, Part A. It may be preferred to cross couple a species in which the side chain is not fully elaborated, then to complete the elaboration, for example as described in Example 14 and in Example 119.
  • Starting material enol phosphates of formula V may be prepared and used by methods similar to those described in Jones et al. , J. Med. Chem. (1992), 25.(5), 931-938; and the corresponding reagents of formula VI may be obtained by conventional methods from bromides of formula XXIII in which X is bromo.
  • a starting material iodide of formula VII in which A is S may be prepared in a manner similar to that described in Example 11, parts A and B, and the boronic acid of formula VIII may be obtained from a compound of formula XXIII using a procedure similar to that of Example 11, part C.
  • An organolithium compound of formula IX may be prepared by transmetallation of the corresponding bromide, which itself may be obtained by bromination of the compound corresponding to formula IX, but with hydrogen in the place of lithium.
  • A is S
  • the procedure may be carried out in a manner similar to that described in Example 10, parts A and B.
  • a starting material of formula XI in which X 2 is 0 or S may be obtained by deprotection of X 2 of a corresponding compound in which X 2 bears a protecting group.
  • X 2 When X 2 is O, it may be protected as a silyl ether, as described in Example 29, or as a methyl ether as described in several of the examples and cleaved by a variety of methods including by using pyridine hydrochloride (Example 5) , aluminum chloride and ethanethiol (Examples 9, 13, 15, 17, 18, 24, 26 and 28, part C) , or boron tribromide (see below) .
  • a starting material of formula XIII in which X 3 is 0 or S may be obtained by deprotection of X 3 of a corresponding compound in which X 3 bears a protecting group.
  • X 3 when X 3 is O, it may be protected as a methyl ether and liberated by treatment with sodium thioethoxide (Example 28, part A), aluminum chloride and ethanethiol, or pyridine hydrochloride, depending upon the groups present in other parts of the molecule.
  • X 3 are O or S may be obtained by deprotection of X 2 and X 3 of a corresponding compound in which X 2 and X 3 bear protecting groups.
  • X 2 and X 3 are both 0, they may both be protected as methyl ethers and simultaneously deprotected by treatment with aluminum chloride and ethane ⁇ thiol (Example 3) with boron tribromide (Examples 8 and 10) or with pyridine hydrochloride (Examples 11 and 12) .
  • a starting material compound of formula XXV typically is prepared by aeylation of a compound of formula XXIV
  • the diether 3- (4-methoxybenzoyl) - 2- (4-methoxyphenyl)benzo[Jb] thiophene described at Example 3, part B may be treated with boron tribromide in dichloromethane at -10 °C (1 hour) to afford the monoether 2- (4-hydroxyphenyl) - 3- (4-methoxybenzoyl)benzo[jb] thiophene, whereas treatment with sodium thioethoxide (Example 28, part A) affords the isomeric monoether 3- (4-hydroxybenzoyl) -2- (4-methoxyphenyl)benzo[Jb] - thiophene.
  • Treatment with boron tribromide under less mild conditions (0°, 6 hours, see Example 8, part C) or with aluminum chloride and ethanethiol cleaves both ethers (Example 3, part C) .
  • the compounds of the invention are isolated best in the form of acid addition salts.
  • Salts of the compounds of formula I formed with acids such as those mentioned above are useful as pharmaceutically acceptable salts for administration of the antithrombotic agents and for preparation of formulations of these agents.
  • Other acid addition salts may be prepared and used in the isolation and purification of the compounds.
  • optically active isomers and diastereomers of the compounds of formula I are also considered part of this invention.
  • Such optically active isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures . This resolution can be carried out by derivatization with a chiral reagent followed by chromatography or by repeated crystallization. Removal of the chiral auxiliary by standard methods affords substantially optically pure isomers of the compounds of the present invention or their precursors. Further details regarding resolutions can be obtained in Jacques, et al. , Enantiomers. Racemates, and Resolutions. John Wiley & Sons, 1981.
  • the compounds of the invention are believed to selectively inhibit thrombin over other proteinases and nonenzyme proteins involved in blood coagulation without appreciable interference with the body's natural clot lysing ability (the compounds have a low inhibitory effect on fibrinolysis) . Further, such selectivity is believed to permit use with thrombolytic agents without substantial interference with thrombolysis and fibrinolysis.
  • the invention in one of its aspects provides a method of inhibiting thrombin in mammals comprising administering to a mammal in need of treatment an effective (thrombin inhibiting) dose of a compound of formula I.
  • the invention provides a method of treating a thromboembolic disorder comprising administering to a mammal in need of treatment an effective (thromboembolic disorder therapeutic and/or prophylactic amount) dose of a compound of formula I.
  • the invention in another of its aspects provides a method of inhibiting coagulation in mammals comprising administering to a mammal in need of treatment an effective (coagulation inhibiting) dose of a compound of formula I.
  • the thrombin inhibition, coagulation inhibition and thromboembolic disorder treatment contemplated by the present method includes both medical therapeutic and/or prophylactic treatment as appropriate.
  • the invention relates to treatment, in a human or animal, of conditions where inhibition of thrombin is required.
  • the compounds of the invention are expected to be useful in animals, including man, in treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues. Disorders in which the compounds have a potential utility are in treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues.
  • disorders in which the compounds have a potential utility, in treatment and/or prophylaxis include venous thrombosis and pulmonary embolism, arterial thrombosis, such as in myocardial ischemia, myocardial infarction, unstable angina, thrombosis-based stroke and peripheral arterial thrombosis.
  • the compounds have expected utility in the treatment or prophylaxis of atherosclerotic disorders (diseases) such as coronary arterial disease, cerebral arterial disease and peripheral arterial disease.
  • the compounds are expected to be useful together with thrombolytics in myocardial infarction.
  • the compounds have expected utility in prophylaxis for reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary bypass operations. Further, the compounds have expected utility in prevention of rethrombosis after microsurgery. Further, the compounds are expected to be useful in anticoagulant treatment in connection with artificial organs and cardiac valves. Further, the compounds have expected utility in anticoagulant treatment in hemodialysis and disseminated intravascular coagulation. A further expected utility is in rinsing of catheters and mechanical devices used in patients in vivo, and as an anticoagulant for preservation of blood, plasma and other blood products in vitro .
  • the compounds have expected utility in other diseases where blood coagulation could be a fundamental contributing process or a source of secondary pathology, such as cancer, including metastasis, inflammatory diseases, including arthritis, and diabetes.
  • the anti-coagulant compound is administered orally or parenterally, e.g. by intravenous infusion (iv) , intramuscular injection (im) or subcutaneously (sc) .
  • a typical daily dose for each of the above utilities is between about 0.01 mg/kg and about 1000 mg/kg.
  • the dose regimen may vary e.g. for prophylactic use a single daily dose may be administered or multiple doses such as 3 or 5 times daily may be appropriate.
  • a compound of the invention is administered by iv infusion at a rate between about 0.01 mg/kg/h and about 20 mg/kg/h and preferably between about 0.1 mg/kg/h and about 5 mg/kg/h.
  • the method of this invention also is practiced in conjunction with a clot lysing agent e.g. tissue plasminogen activator (t-PA) , modified t-PA, streptokinase or urokinase.
  • a clot lysing agent e.g. tissue plasminogen activator (t-PA) , modified t-PA, streptokinase or urokinase.
  • tissue plasminogen activator t-PA
  • modified t-PA modified t-PA
  • streptokinase or urokinase.
  • a clot lysing agent is usually employed.
  • a compound of the invention can be administered prior to or along with the lysing agent or subsequent to its use, and preferably further is administered along with aspirin to prevent the reoccurrence of clot formation.
  • the method of this invention is also practiced in conjunction with a platelet glycoprotein receptor (Ilb/IIIa) antagonist, that inhibits platelet aggregation.
  • a compound of the invention can be administered prior to or along with the lib/Ilia antagonist or subsequent to its use to prevent the occurrence or reoccurrence of clot formation.
  • the method of this invention is also practiced in conjunction with aspirin.
  • a compound of the invention can be administered prior to or along with aspirin or subsequent to its use to prevent the occurrence or reoccurrence of clot formation.
  • a compound of the present invention is administered in conjunction with a clot lysing agent and aspirin.
  • This invention also provides pharmaceutical formulations for use in the above described therapeutic method.
  • compositions of the invention comprise an effective thrombin inhibiting amount of a compound of formula I in association with a pharmaceutically acceptable carrier, excipient or diluent.
  • a pharmaceutically acceptable carrier e.g. physiological saline (0.9 percent), 5 percent dextrose, Ringer's solution and the like.
  • the compound of the present invention can be formulated in unit dosage formulations comprising a dose between about 0.1 mg and about 1000 mg.
  • the compound is in the form of a pharmaceutically acceptable salt such as for example the sulfate salt, acetate salt or a phosphate salt.
  • An example of a unit dosage formulation comprises 5 mg of a compound of the present invention as a pharmaceutically acceptable salt in a 10 ml sterile glass ampoule.
  • Another example of a unit dosage formulation comprises about 10 mg of a compound of the present invention as a pharmaceutically acceptable salt in 20 ml of isotonic saline contained in a sterile ampoule.
  • the compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal.
  • the compounds of the present invention are preferably formulated prior to administration.
  • Another embodiment of the present invention is a pharmaceutical formulation comprising an effective amount of a novel compound of formula I or a pharmaceutically acceptable salt or solvate thereof in association with a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • the active ingredient in such formulations comprises from 0.1 percent to 99.9 percent by weight of the formulation.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions of this invention are prepared by known procedures using well known and readily available ingredients.
  • the compositions of this invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container.
  • the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, (as a solid or in a liquid medium) , soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders, and the like.
  • Active ingredient means a compound according to Formula I or a pharmaceutically acceptable salt or solvate thereof.
  • Formulation 1 Hard gelatin capsules are prepared using the following ingredients: Quantity (m ⁇ /capsule)
  • Active ingredient 250 Starch, dried 200 Magnesium stearate 10 Total 460 mg
  • Formulation 2 A tablet is prepared using the ingredients below:
  • the components are blended and compressed to form tablets each weighing 665 mg.
  • Formulation 3 An aerosol solution is prepared containing the following components :
  • Propellant 22 (Chlorodifluoromethane) 70.00
  • the active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30 °C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.
  • Formulation 4 Tablets, each containing 60 mg of active ingredient, are made as follows: Active ingredient 60 mg
  • the active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
  • the aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve.
  • the granules so produced are dried at 50 °C and passed through a No. 18 mesh U.S. Sieve.
  • the sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
  • Capsules each containing 80 mg of active ingredient, are made as follows:
  • the active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
  • Formulation 6 Suppositories, each containing 225 mg of active ingredient, are made as follows: Active ingredient 225 mg
  • the active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste.
  • the benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
  • Formulation 8 An intravenous formulation may be prepared as follows:
  • the solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute.
  • the ability of the compounds of the present invention to be an effective and orally active thrombin inhibitor are evaluated in one or more of the following assays.
  • the compounds provided by the invention selectively inhibit the action of thrombin in mammals.
  • the inhibition of thrombin is demonstrated by in vi tro inhibition of the amidase activity of thrombin as measured in an assay in which thrombin hydrolyzes the chromogenic substrate,
  • the assay is carried out by mixing 50 ⁇ l buffer
  • Standard curves are constructed by plotting free thrombin concentration against hydrolysis rate. The hydrolysis rates observed with test compounds are then converted to "free thrombin" values in the respective assays by use of the standard curves.
  • the bound thrombin (bound to test compound) is calculated by subtracting the amount of free thrombin observed in each assay from the known initial amount of thrombin used in the assay.
  • the amount of free inhibitor in each assay is calculated by subtracting the number of moles of bound thrombin from the number of moles of added inhibitor
  • the Kass value is the hypothetical equilibrium constant for the reaction between thrombin and the test compound (I) .
  • Kass is calculated for a range of concentrations of test compounds and the mean value reported in units of liter per mole.
  • a thrombin inhibiting compound of formula I of the instant insertion exhibits a Kass of 0.03 X 10 ⁇ L/mole or much greater.
  • the compound of Example 3 was found to have a Kass of 5.0 X 10 ⁇ L/mole
  • the compound of Example 164 was found to have a Kass of 526 X 10 6 L/mole.
  • Human factors X, Xa, IXa, XIa, and Xlla are purchased from Enzyme Research Laboratories, South Bend, Indiana; human urokinase from Leo Pharmaceuticals, Denmark; and recombinant activated Protein C (aPC) is prepared at Eli Lilly and Co. substantially according to U.S. Patent 4,981,952.
  • Chromogenic substrates N-Benzoyl-Ile-Glu-Gly- Arg-p-nitroanilide (for factor Xa) ; N-Cbz-D-Arg-Gly-Arg-p- nitroanilide (for factor IXa assay as the factor Xa substrate); Pyroglutamyl-Pro-Arg-p-nitroanilide (for Factor XIa and for aPC) ; H-D-Pro-Phe-Arg-p-nitroanilide (for factor Xlla) ; and Pyroglutamyl-Gly-Arg-p-nitroanilide (for urokinase) ; are purchased from Kabi Vitrum, Sweden, or from Midwest Biotech, Fishers, Indiana.
  • Bovine trypsin is purchased from Worthington Biochemicals, Freehold, New Jersey, and human plasma kallikrein from Kabi Vitrum, Swiss, Sweden.
  • Chromogenic substrate H-D-Pro-Phe-Arg-p- nitroanilide for plasma kallikrein is purchased from Kabi Vitrum, Swiss, Sweden.
  • N-Benzoyl-Phe-Val-Arg-p- nitroanilide, the substrate for human thrombin and for trypsin is synthesized according to procedures described above for the compounds of the present invention, using known methods of peptide coupling from commercially available reactants, or purchased from Midwest Biotech, Fishers, Indiana.
  • plasmin Human plasmin is purchased from Boehringer Mannheim, Indianapolis, Indiana; nt-PA is purchased as single chain activity reference from American Diagnostica, Greenwich, Connecticut; modified-t-PA6 (mt-PA6) is prepared at Eli Lilly and Company by procedure known in the art (See, Burck, et al. , J. Biol. Chem.. 265, 5120-5177 (1990) .
  • Plasmin chromogenic substrate H-D-Val-Leu-Lys-p-nitroanilide and tissue plasminogen activator (t-PA) substrate H-D-Ile- Pro-Arg-p-nitroanilide are purchased from Kabi Vitrum, Sweden.
  • Glu, Gly, Pro, Arg, Phe, Val, Leu and Lys are used to indicate the corresponding amino acid group isoleucine, glutamic acid, glycine, proline, arginine, phenylalanine, valine, leucine and lysine, respectively.
  • Thrombin inhibitors preferably should spare fibrinolysis induced by urokinase, tissue plasminogen activator (t-PA) and steptokinase.
  • Materials Dog plasma is obtained from conscious mixed-breed hounds (either sex Hazelton-LRE, Kalamazoo, Michigan, U.S.A.) by venipuncture into 3.8 percent citrate.
  • Fibrinogen is prepared from fresh dog plasma and human fibrinogen is prepared from in-date ACD human blood at the fraction 1-2 according to previous procedures and specifications. Smith, Biochem. J.. 185, 1-11 (1980); and Smith, et al. , Biochemistry. 11, 2958-2967, (1972) .
  • Human fibrinogen (98 percent pure/plasmin free) is from American Diagnostica, Greenwich, Connecticut. Radiolabeling of fibrinogen 1-2 preparations is performed as previously reported. Smith, et al., Biochemistry. 11.
  • Urokinase is purchased from Leo Pharmaceuticals, Denmark, as 2200 Ploug units/vial. Streptokinase is purchased from Hoechst-Roussel Pharmaceuticals, Somerville, New Jersey. Methods - Effects on Lvsis of Human Plasma Clots bv t-PA Human plasma clots are formed in micro test tubes by adding 50 ⁇ L thrombin (73 NIH unit/mL) to 100 ⁇ L human plasma which contains 0.0229 ⁇ Ci 125-iodine labeled fibrinogen.
  • Clot lysis is studied by overlaying the clots with 50 ⁇ L of urokinase or streptokinase (50, 100, or 1000 unit/mL) and incubating for 20 hours at room temperature. After incubation the tubes are centrifuged in a Beckman Microfuge. 25 ⁇ L of supernate is added into 1.0 mL volume of 0.03 M tris/0.15 M NaCl buffer for gamma counting. Counting controls 100 percent lysis are obtained by omitting thrombin (and substituting buffer) . The thrombin inhibitors are evaluated for possible interference with fibrinolysis by including the compounds in the overlay solutions at 1, 5, and 10 ⁇ g/mL concentrations. Rough approximations of IC50 values are estimated by linear extrapolations from data points to a value which would represent 50 percent of lysis for that particular concentration of fibrinolytic agent.
  • Dog plasma and rat plasma are obtained from conscious mixed- breed hounds (either sex, hazelton-LRE, Kalamazoo, Michigan, U.S.A.) or from anesthetized male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc., Indianapolis, Indiana, U.S.A.) by venipuncture into 3.8 percent citrate.
  • Fibrinogen is prepared from in-date ACD human blood as the fraction 1-2 according to previous procedures and specifications. Smith, Biochem. J.. 1£5, 1-11 (1980); and Smith, et al. , Biochemistr y . 11, 2958-2967 (1972) .
  • Human fibrinogen is also purchased as 98 percent pure/plasmin free from American Diagnostica, Greenwich, Connecticut.
  • Coagulation reagents Actin, Thromboplastin, Innovin and Human plasma are from Baxter Healthcare Corp., Dade Division, Miami, Florida.
  • Bovine thrombin from Parke-Davis (Detroit, Michigan) is used for coagulation assays in plasma.
  • Coagulation assay procedures are as previously described. Smith, et al. , Thrombosis Research. 50, 163-174 (1988). A CoAScreener coagulation instrument (American LABor, Inc.) is used for all coagulation assay measurements.
  • the prothrombin time (PT) is measured by adding 0.05 mL saline and 0.05 mL Thromboplastin-C reagent or recombinant human tissue factor reagent (Innovin) to 0.05 mL test plasma.
  • the activated partial thromboplastin time is measured by incubation of 0.05 mL test plasma with 0.05 mL Actin reagent for 120 seconds followed by 0.05 mL CaCl2 (0.02 M) .
  • the thrombin time is measured by adding 0.05 mL saline and 0.05 mL thrombin (10 NIH units/mL) to 0.05 mL test plasma.
  • the compounds of formula I are added to human or animal plasma over a wide range of concentrations to determine prolongation effects on the APTT, PT, and TT assays. Linear extrapolations are performed to estimate the concentrations required to double the clotting time for each assay. For preferred compounds of the instant invention, a concentration of 30 ng/mL or less typically is sufficient to double the TT.
  • mice Male Sprague Dawley rats (350-425 gm, Harlan Sprague Dawley Inc., Indianapolis, IN) are anesthetized with xylazine (20 mg/kg, s.c.) and keta ine (120 mg/kg, s.c.) and maintained on a heated water blanket (37 °C) .
  • the jugular vein(s) is cannulated to allow for infusions .
  • the left jugular vein and right carotid artery are cannulated with 20 cm lengths of polyethylene PE 60 tubing.
  • Blood is circulated through the shunt for 15 min before the thread is carefully removed and weighed. The weight of a wet thread is subtracted from the total weight of the thread and thrombus (see J.R. Smith, Br J Pharmacol. 12: 29 , 1982) .
  • preferred compounds of the instant invention reduce the net clot weight to approximately 25-30% of control, or even lower, at an i.v. dose of 33.176 ⁇ mol/kg/h.
  • the carotid arteries are isolated via a midline ventral cervical incision.
  • a thermocouple is placed under each artery and vessel temperature is recorded continuously on a strip chart recorder.
  • a cuff of tubing (0.058 ID x 0.077 OD x 4 mm, Baxter Med. Grade Silicone) , cut longitudinally, is placed around each carotid directly above the thermocouple.
  • FeCl 3 hexahydrate is dissolved in water and the concentration (20 percent) is expressed in terms of the actual weight of
  • thrombin inhibitors inhibit thrombin and, at higher concentrations, may inhibit other serine proteases, such as plasmin and tissue plasminogen activator.
  • the rate of spontaneous thrombolysis is determined by implanting a labeled whole blood clot into the pulmonary circulation. Rat blood (1 mL) is mixed rapidly with bovine thrombin (4 IU, Parke Davis) and 125 I human Fibrogen (5 ⁇ ci, ICN) , immediately drawn into silastic tubing and incubated at 37 °C for 1 hour.
  • the aged thrombus is expelled from the tubing, cut into 1 cm segments, washed 3X in normal saline and each segment is counted in a gamma counter.
  • a segment with known counts is aspirated into a catheter that is subsequently implanted into the jugular vein.
  • the catheter tip is advanced to the vicinity of the right atrium and the clot is expelled to float into the pulmonary circulation.
  • One hour after implant, the heart and lungs are harvested and counted separately.
  • Thrombolysis is expressed as a percentage where:
  • % Thrombolysis (injected ct>m - lung com) x 100 injected cpm
  • the fibrinolytic dissolution of the implanted clot occurs time-dependently (see J.P. Clozel, Cardiovas . Pharmacol. , 12:520, 1988) .
  • Plasma thrombin time (TT) and activated partial thromboplastin time (APTT) are measured with a fibrometer. Blood is sampled from a jugular catheter and collected in syringe containing sodium citrate (3.8 percent, 1 part to 9 parts blood) . To measure TT, rat plasma (0.1 mL) is mixed with saline (0.1 mL) and bovine thrombin (0.1 mL, 30 U/mL in TRIS buffer; Parke Davis) at 37 °C.
  • APTT For APTT, plasma (0.1 mL) and APTT solution (0.1 mL, Organon Teknika) are incubated for 5 minutes (37 °C) and CaCl 2 (0.1 mL, 0.025 M) is added to start coagulation. Assays are done in duplicate and averaged.
  • plasma thrombin time serves as a substitute for the assay of parent compound on the assumption that observed increments in TT resulted from thrombin inhibition by parent only.
  • the time course of the effect of the thrombin inhibitor upon TT is determined after i.v bolus administration to anesthetized rats and after oral treatment of fasted conscious rats. Due to limitations of blood volume and the number of points required to determine the time course from time of treatment to the time when the response returns to pretreatment values, two populations of rats are used. Each sample population represents alternating sequential time points . The average TT over the time course is used to calculate area under the curve (AUC) .
  • AUC area under the curve
  • the index of bioavailability is calculated by the formula shown below and is expressed as percent relative activity.
  • the area under the curve (AUC) of the plasma TT time course is determined and adjusted for the dose. This index of bioavailability is termed "% Relative Activity” and is calculated as
  • Compound solutions are prepared fresh daily in normal saline and are injected as a bolus or are infused starting 15 minutes before and continuing throughout the experimental perturbation which is 15 minutes in the arteriovenous shunt model and 60 minutes in the FeCl 3 model of arterial injury and in the spontaneous thrombolysis model.
  • Bolus injection volume is 1 mL/kg for i.v., and 5 mL/kg for p.o., and infusion volume is 3 mL/hr.
  • Results are expressed as means +/- SEM. One-way analysis of variance is used to detect statistically significant differences and then Dunnett's test is applied to determine which means are different. Significance level for rejection of the null hypothesis of equal means is P ⁇ 0.05.
  • Test compound is formulated immediately prior to dosing by dissolving in sterile 0.9 percent saline to a 5 mg/mL preparation. Dogs are given a single 2 mg/kg dose of test compound by oral gavage. Blood samples (4.5 mL) are taken from the cephalic vein at 0.25, 0.5, 0.75, 1, 2, 3, 4 and 6 hours after dosing. Samples are collected in citrated Vacutainer tubes and kept on ice prior to reduction to plasma by centrifugation. Plasma samples are analyzed by HPLC MS.
  • Plasma concentration of test compound is recorded and used to calculate the pharmacokinetic parameters : elimination rate constant, Ke; total clearance, Clt; volume of distribution, V D ; time of maximum plasma test compound concentration, Tmax; maximum concentration of test compound of Tmax, Cmax; plasma half-life, to.5; and area under the curve, A.U.C.; fraction of test compound absorbed, F.
  • the left jugular vein and common carotid artery are isolated through a left mediolateral neck incision.
  • Arterial blood pressure (ABP) is measured continuously with a precalibrated Millar transducer (model (MPC-500, Millar Instruments, Houston, TX, U.S.A.) inserted into the carotid artery.
  • the jugular vein is cannulated for blood sampling during the experiment.
  • the femoral veins of both hindlegs are cannulated for administration of test compound.
  • a left thoracotomy is performed at the fifth intercostal space, and the heart is suspended in a pericardial cradle.
  • a 1- to 2-cm segment of the left circumflex coronary artery is isolated proximal to the first major diagonal ventricular branch.
  • a 26-gauge needle-tipped wire anodal electrode (Teflon-coated, 30-gauge silverplated copper wire) 3-4 mm long is inserted into the LCX and placed in contact with the intimal surface of the artery (confirmed at the end of the experiment) .
  • the stimulating circuit is completed by placing the cathode in a subcutaneous (s.c.) site.
  • An adjustable plastic occluder is placed around the LCX, over the region of the electrode.
  • a precalibrated electromagnetic flow probe (Carolina Medical Electronics, King, NC, U.S.A.) is placed around the LCX proximal to the anode for measurement of coronary blood flow (CBF) .
  • CBF coronary blood flow
  • the occluder is adjusted to produce a 40-50 percent inhibition of the hyperemic blood flow response observed after 10-s mechanical occlusion of the LCX. All hemodynamic and ECG measurements are recorded and analyzed with a data acquisition system (model M3000, Modular Instruments, Malvern, PA. U.S.A.) .
  • Thrombus Formation and Compound Administration Regimens Electrolytic injury of the intima of the LCX is produced by applying 100- ⁇ A direct current (DC) to the anode. The current is maintained for 60 min and then discontinued whether the vessel has occluded or not. Thrombus formation proceeds spontaneously until the LCX is totally occluded (determined as zero CBF and an increase in the S-T segment) . Compound administration is started after the occluding thrombus is allowed to age for 1 hour. A 2-hour infusion of the compounds of the present invention at doses of 0.5 and 1 mg/kg/hour is begun simultaneously with an infusion of thrombolytic agent (e.g. tissue plasminogen activator, streptokinase, APSAC) .
  • thrombolytic agent e.g. tissue plasminogen activator, streptokinase, APSAC
  • the device is used to make 2 horizontal incisions in the gingiva of either the upper or lower left jaw of the dog. Each incision is 3 mm wide x 2 mm deep. The incisions are made, and a stopwatch is used to determine how long bleeding occurs. A cotton swab is used to soak up the blood as it oozes from the incision. Template bleeding time is the time from incision to stoppage of bleeding. Bleeding times are taken just before administration of test compound (0 min) , 60 min into infusion, at conclusion of administration of the test compound (120 min), and at the end of the experiment.
  • AIBN azobisisobutyronitrile
  • DIBAL-H diisobutyl aluminum hydride
  • FAB Fast Atom Bombardment (Mass Spectrascopy)
  • LAH lithium aluminum hydride
  • NBS N-bromosuccinimide
  • PPA polyphosphoric acid
  • i-Pr isopropyl
  • Si ⁇ 2 silica gel
  • SM starting material
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • TIPS triisopropylsilyl
  • PrepLC indicates preparative liquid chromatography using "Prep Pak (TM) " silica cartridges; radial chromatography indicates preparative chromatography using a “Chromatotron (TM) " instrument.
  • Example 3 2- (4- methoxyphenyl)benzo [b] thiophene (Example 3; Part A) and 4- [3- (1-pyrrolidinyl)propyl]benzoic acid hydrochloride in 33% yield as a viscous oil.
  • Example 3 the free base of the title compound was prepared from 2- (4-hydroxyphenyl)benzo [b] thiophen-3-yl 4- [3- (1-pyrrolidinyl)propyl]phenyl ketone (Part B) and l-(2- chloroethyl)pyrrolidine hydrochloride in 36% yield as a viscous oil following radial chromatography (Si ⁇ 2 ,* gradient of 5-15% MeOH in CH 2 CI 2 ) .
  • the free base was converted to the dioxalate salt according to the conditions described in
  • Example 6 2 - [ 4 - [ 2 - ( 1 - Pyrrolidinyl ) ethoxy] phenyl ] benzo [ ] thio ⁇ phen- 3 -yl 4 - [ ( 1-Pyrrolidinyl ) ethyl ] phenyl Ketone Dioxalate .
  • the free base of the title compound was prepared from 4- [ (1-pyrrolidinyl)methyl]benzoic acid hydrochloride (Part B) and 1-[2-[4- (benzo [b]thiophen-2- yl)phenoxy]ethyl]pyrrolidine (Example 4, Part A) in 44% yield.
  • the free base was converted to the dioxalate salt according to the conditions described in Example 1, Part C.
  • the free base of the title compound was prepared from 4- [2- (1-pyrrolidinyl)ethyl]benzoic acid hydrochloride (Part B) and 1- [2- [4- (benzo[ ] thiophen-2- yl)phenoxy]ethyl] yrrolidine (Example 4, Part A) in 45% yield.
  • the free base was converted to the dioxalate salt according to the conditions described in Example 1, Part C.
  • the free base of the title compound was prepared from 2- (4-hydroxyphenyl)benzo [b] thiophen-3-yl 3-methyl-4-hydroxyphenyl ketone (Part C) and l-(2- chloroethyl)pyrrolidine hydrochloride in 83% yield as an oil following radial chromatography (Si ⁇ 2 ,* 10% MeOH and 0.5% TEA in CH 2 CI 2 ) .
  • the free base was converted to the dioxalate salt according to the conditions described in Example 1, Part C.
  • Example 3 By essentially following the procedure detailed in Example 1, Part C, the title compound was prepared from 6- chloronicotinic acid and 2- (4-methoxyphenyl) enzo [b] thiophene (Example 3, Part A) in 31% yield as a yellow solid following flash chromatography (Si0 2 ; CH2CI2) .
  • Example 3 the free base of the title compound was prepared from 2- (4-hydroxyphenyl)benzo[b] thiophen-3-yl 6- [2- (1-pyrrolidinyl) ethoxy)pyrid-3-yl ketone (Part C) and l-(2- chloroethyl)pyrrolidine hydrochloride in 84% yield as an oil following radial chromatography (Si0 2 ; gradient of 5-20% MeOH in THF) .
  • the free base was converted to the dioxalate salt according to the conditions described in Example 1, Part C.
  • Example 5 the title compound was prepared from 2- (4- methoxyphenyl) -3- (4-methoxyphenoxy)benzo [b] thiophene (Part D) in 87% yield following radial chromatography ⁇ Si0 2 ; 25% EtOAc in hexanes) .
  • the free base of the title compound was prepared from 4- [1- [2- (4-hydroxyphenyl)benzo[b]thiophen-3- yl]ethenyl]phenol (Part B) and 1- (2-chloroethyl)pyrrolidine hydrochloride in 67% yield as an oil following radial chromatography (Si0 2 ; gradient of 2-10% MeOH in CH 2 CI 2 ) -
  • the free base was converted to the dioxalate salt according to the conditions described in Example 1, Part C.
  • Example 3 2- (4-methoxyphenyl)benzo[b]thiophene
  • Example 3 4- [2- (hexahydro-lH-azepin-1-yl)ethoxy]benzoic acid hydrochloride in 35% yield as an oil following radial chromatography (Si ⁇ 2 ; gradient of 1-10% isopropanol in CH 2 C1 2 ).
  • Example 3 By essentially following the procedure detailed in Example 1, Part C, the title compound was prepared from 2- (4-methoxyphenyl)benzo[b] thiophene (Example 3, Part A) and 4- [2- (1-pyrrolidinyl)ethoxy]benzoic acid hydrochloride in 59% yield as an oil following radial chromatography (Si ⁇ 2 ; gradient of 2-5% MeOH in CH 2 C1 2 ) .
  • Example 1 the title compound was prepared from 5- (benzo [b] thiophen-2-yl)pyrid-2-yl 2- (1 -pyrrolidinyl) ethyl ether (Part B) and 4- [2- (1-pyrrolidinyl) -ethoxy] benzoic acid hydrochloride in 30% yield as a solid following flash chromatography (Si ⁇ 2; 5% MeOH in CHCI3) .
  • the free base was converted to the dioxalate salt according to the conditions outlined in Example 1, Part C.
  • Example 28 By essentially following the procedure outlined in Example 3, part D, the title compound was prepared in 96% yield from 4-hydroxyphenyl 2- (4-methoxyphenyl)benzo [b] - thiophen-3-yl ketone (Example 28, Part A) to yield an off- white foam following column chromatography (Si ⁇ 2; gradient 0- 5% MeOH in EtOAc) .
  • Example 28 By essentially following the procedure outlined in Example 3, part D, the title compound was prepared from 4- hydroxyphenyl 2- (4-methoxyphenyl)benzo[b] thiophen-3-yl ketone (Example 28, Part A) and 2-diethylaminoethyl chloride in 86% yield. Flash chromatography [Si ⁇ 2; gradient 1-4% of (1:1
  • Example 2 part D, the title compound was prepared in 91% yield from 4- [2- (diethylamino) ethoxy]phenyl 2- [4- [2- (1-pyrro ⁇ lidinyl)ethoxy]phenyl]benzo[b] thiophen-3-yl ketone (Part C) . Flash chromatography [Si ⁇ 2; 80% THF in hexanes with 3% TEA (v/v) ] gave a white gummy solid which was converted to the dioxalate salt following the method described in Example 1, part C.
  • Ci8H25NO3'0.73NaCl C, 62.47, H, 7.28, N, 4.05. Found: C, 62.92, H, 7.47, N, 4.15.
  • the reaction was then quenched at 0 C by addition of 80 ⁇ L of H2O, followed by 80 ⁇ L of 15% NaOH, and then an additional 240 ⁇ L of H2O (Fieser workup) .
  • This mixture was then filtered over a pad of silica gel and washed with THF. The filtrate was concentrated to dryness under reduced pressure.
  • the crude alcohol was dissolved in 21.0 mL of anhydrous CH2CI2 and cooled to 0 °C. To this was added 2.30 mL (14.7 mmol) of triethylsilane, and the reaction mixture was stirred for 5 in, followed by a dropwise addition of 1.60 mL (21.0 mmol) of trifluoroacetic acid.
  • a -0.5 M solution of sodium thioethoxide was prepared by adding ethanethiol (1.60 mL, 21.4 mmol) to a suspension of 60% NaH dispersion in mineral oil (769 mg, 19.2 mmol) in 40 mL of anhydrous DMF at 0 C. The ice bath was removed and the solution was stirred at room temperature for 30 min. The 0.5 M solution of sodium thioethoxide was then added dropwise to the solution of 4.00 g (10.7 mmol) of 2- (4-methoxyphenyl) - benzo[b]thiophen-3-yl 4-methoxyphenyl ketone in 10.0 mL of anhydrous DMF at room temperature.
  • the reaction mixture was heated at 85 °C for 3 h, then allowed to cool to room temperature, and acidified with 20 mL of 1.0 N HCl. To this was added 200 mL of H2O and the mixture was extracted with EtOAc (3 x 400 mL) . The combined organic layers were washed with 200 mL of brine, dried over MgS ⁇ 4, and concentrated under reduced pressure.
  • the crude product was purified by PrepLC (30% EtOAc in hexanes) to afford 3.017 g of the title compound (8.37 mmol, 78%) as a yellow foam.
  • reaction mixture was stirred for 3 days and then filtered through a medium frit, concentrated at reduced pressure, and chromatographed on silica gel (1:1 TEA/MeOH in THF, 0 to 10%) to give 2.70 g (4.7 mmol, 90%) of a brown foam.
  • reaction mixture was poured into 50 mL of water, saturated with sodium chloride, and extracted with three 50 mL portions of THF. The combined organic layers were washed with brine, dried with anhydrous magnesium sulfate, and concentrated to give 1.32 g (95% crude yield) of a brown foam.
  • Diisobutylaluminum hydride (1.0 M in toluene, 3.59 mL) was added dropwise to a stirred solution of 3-[4-[2-(l- piperidinyl)ethoxy]benzoyl] -2- [4- [2- (1-pyrrolidinyl)ethoxy] - phenyl]benzo[b]thiophene-6-carboxylic acid methyl ester (550 mg, 0.898 mmol) in anhydrous THF (6 mL) at 0 °C under argon. The mixture was stirred at 0 °C for 1.5 h.
  • Triethylsilane (0.946 mL, 5.92 mmol) and trifluoroacetic acid (0.652 mL, 8.46 mmol) were added consecutively to a stirred solution of ⁇ (3) -[4- [2- (1-piperidinyl)ethoxy] - phenyl] -2- [4- [2- (1-pyrrolidinyl)ethoxy]phenyl]benzo[b] - thiophene-3, 6-dimethanol (Part A) (496 mg, 0.846 mmol) in dry 1,2-dichloroethane (5 mL) at 0 °C under argon atmosphere, and the resultant solution was stirred at 0 °C for 6 h.
  • the title compound was prepared from 6-methoxy-2- [4- [2- (l-pyrrolidinyl)ethoxy]phenyl]benzo[ ] thiophene (Example 1, Part B) and 6-chloronicotinic acid in 51% yield (based on 6-methoxy-2- [4- [2- (1-pyrrolidinyl) ethoxy] henyl] - benzo [b] thiophene) by essentially following the proceedures described in Example 1, Part C.
  • the aryl bromide of Part A (146 mg, 0.608 mmol) was added to a stirred suspension of magnesium ribbons (13.9 mg, 0.570 mmol) in anhydrous THF (2 mL) under argon atmosphere, followed by the addition of a small iodine crytal.
  • the resultant mixture was heated in an oil bath at 60-65 °C for 2 h to form a homogeneous Grignard solution.
  • the Grignard solution was cooled to room temperature before it was added to a stirred solution of the benzothiophene of Part B (150 mg, 0.380 mmol) in anhydrous THF (2 mL) at 0 °C under argon atmosphere.
  • DIBAL-H (0.911 mL, 1 M in toluene) was added to a stirred solution of the ketone of Part C (310 mg, 0.607 mmol) in anhydrous CH2CI2 (4 mL) at 0 °C under nitrogen atmosphere, and the resultant solution was stirred at 0 °C for 40 min.
  • the reaction mixture was treated sequentially with MeOH (0.5 mL) and saturated aqueous Rochelle's salt solution (10 mL) , and then the two-layered solution was stirred vigorously at room temperature for 1 h. After extraction with EtOAc (50 mL) , the organic layer was dried over MgS04, filtered, and concentrated to yield 280 mg of the corresponding alcohol.
  • AIBN (79 mg) was a ed to a stirred suspension of methyl 3-bromo-4-methylbenzoate (11.0 g, 48.0 mmol) and NBS (10.3 g, 57.6 mmol) in CCI4 (400 mL) , and the resultant mixture was heated to reflux for 2 h. After cooling to room temperature, the mixture was diluted with hexanes (200 mL) before it was filtered and concentrated to give 14.7 g (crude yield 100%) of methyl 3-bromo-4- (bromomethyl)benzoate. Part of the crude dibromide (14.7 g) was dissolved in anhydrous CH2CI2 (60 mL) .
  • the solution was cooled to 0 °C and treated with pyrrolidine (9.96 mL, 119 mmol), then it was allowed to stir at room temperature for 2 h.
  • the reaction mixture was diluted with EtOAc (500 mL) , washed with half- saturated aqueous NaHC ⁇ 3 (100 mL) , dried over MgS ⁇ 4, filtered, and concentrated to give an oily residue.
  • the crude product was chromatographed on silica [gradient 0-10% EtOH/Et3N (2/1) in THF/hexanes (1/1)] to provide 6.45 g of the pyrrolidinyl ester (45%) as an oil.
  • CS2CO3 (4.89 g, 15.0 mmol) was added to a stirred solution of 2- (4-hydroxyphenyl) -6-methoxybenzo[b] thiophene (1.10 g, 4.29 mmol) and 4- (2-chloroethyl)morpholine hydrochloride (3.20 g, 17.2 mmol) in anhydrous DMF (10 mL) .
  • the resultant suspension was heated in an oil bath at 75 °C for 4 h. After cooling to room temperature, the mixture was diluted with EtOAc (60 mL) , washed with half-saturated aqueous NaCl solution (20 mL) , dried over MgS04, filtered, and concentrated to give a solid residue. Chromatography on silica [gradient 0-15% EtOH/Et3N (2/1) in THF/hexanes (1/1)] provided 1.43 g of the ether (90%) as a solid.
  • Oxalyl chloride (1.11 mL, 12.7 mmol) was added to a stirred suspension of the above benzothiophene (812 mg, 2.53 mmol) in anhydrous CICH2CH2CI (6 mL) , followed by the addition of 2 drops of DMF. The suspension was stirred at room temperature under nitrogen atmosphere for 6 h, then it was concentrated to dryness under vacuum at 50 °C.
  • a sealed tube containing a stirred mixture of the aryl bromide of Example 37, Part E, (283 mg, 0.456 mmol), tetramethlytin (0.316 mL, 2.28 mmol), and tetrakis ( triphenyl ⁇ phosphine )palladium(0) (16 mg, 0.014 mmol) in o-xylene (5 mL) was heated in an oil bath at 155 °C for 1 h. A black precipitate was formed.
  • Methanesulfonyl chloride (2.12 mL, 27.4 mmol) was added to a stirred solution of 4-bromophenethyl alcohol (5.00 g, 24.9 mmol) and anhydrous pyridine (2.21 mL, 27.4 mmol) in anhydrous CH2CI2 (25 mL) at 0 °C under nitrogen atmosphere. Upon the completion of the addition the mixture was allowed to stir at room temperature for 8 h. Then the reaction mixture was cooled to 0 °C and treated with pyrrolidine (10.4 mL, 124 mmol) .
  • Oxalyl chloride (2.57 mL, 29.5 mmol) was added to a stirred suspension of 3-methyl-4-[ (1-pyrrolidinyl) ethyl]- benzoic acid hydrochloride (1.76 g, 5.90 mmol) in anhydrous CICH2CH2CI (12 mL) , followed by the addition of 2 drops of DMF.
  • the suspension was stirred at room temperature under nitrogen atmosphere for 6 h, then it was concentrated to dryness under vacuum at 50 °C.
  • Triisopropylsilyl trifluoromethanesulfonate (35.1 mL, 130 mmol) was added to a stirred solution of 4-bromophenethyl alcohol (20.2 g, 100 mmol) and anhydrous triethylamine (27.8 mL, 200 mmol) in anhydrous CH2CI2 (200 mL) at room temperature under nitrogen atmosphere. The resultant mixture was stirred for 3 h.
PCT/US1996/017995 1995-10-31 1996-10-30 Antithrombotic diamines WO1997025033A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT96940354T ATE284690T1 (de) 1995-10-31 1996-10-30 Antithrombotische diamine
DE69634045T DE69634045T2 (de) 1995-10-31 1996-10-30 Antithrombotische diamine
JP52518397A JP2002500618A (ja) 1995-10-31 1996-10-30 抗血栓性ジアミン
EP96940354A EP0863755B1 (en) 1995-10-31 1996-10-30 Antithrombotic diamines
AU77255/96A AU7725596A (en) 1995-10-31 1996-10-30 Antithrombotic diamines
US09/369,416 US6265575B1 (en) 1995-10-31 1999-08-05 Antithrombotic diamines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US712095P 1995-10-31 1995-10-31
US2825296P 1996-10-09 1996-10-09
US60/007,120 1996-10-09
US60/028,252 1996-10-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/846,647 Continuation-In-Part US6025382A (en) 1995-10-31 1997-04-30 Antithrombotic diamines
US83668097A Continuation 1995-10-31 1997-04-30

Publications (1)

Publication Number Publication Date
WO1997025033A1 true WO1997025033A1 (en) 1997-07-17

Family

ID=26676549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017995 WO1997025033A1 (en) 1995-10-31 1996-10-30 Antithrombotic diamines

Country Status (9)

Country Link
US (3) US6025382A (US06251921-20010626-C00395.png)
EP (1) EP0863755B1 (US06251921-20010626-C00395.png)
JP (1) JP2002500618A (US06251921-20010626-C00395.png)
AT (1) ATE284690T1 (US06251921-20010626-C00395.png)
AU (1) AU7725596A (US06251921-20010626-C00395.png)
CA (1) CA2236007A1 (US06251921-20010626-C00395.png)
DE (1) DE69634045T2 (US06251921-20010626-C00395.png)
ES (1) ES2233982T3 (US06251921-20010626-C00395.png)
WO (1) WO1997025033A1 (US06251921-20010626-C00395.png)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835871A1 (en) * 1996-10-10 1998-04-15 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, formulations, and methods
WO1998048794A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
WO1998055454A2 (en) * 1997-06-05 1998-12-10 Takeda Chemical Industries, Ltd. Benzofurans and benzothophenes as suppressors of neurodegeneration
US6017914A (en) * 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods
EP0980366A1 (en) * 1997-04-30 2000-02-23 Eli Lilly And Company Antithrombotic agents
EP0997460A1 (en) * 1998-10-28 2000-05-03 Eli Lilly And Company Benzothiophene compounds as antithrombotic agents and intermediates
US6172100B1 (en) 1997-04-30 2001-01-09 Eli Lilly And Company Antithrombotic agents
US6265416B1 (en) 1998-10-30 2001-07-24 Eli Lilly And Company Antithrombotic agents
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
US6350774B1 (en) 1997-04-30 2002-02-26 Eli Lilly And Company Antithrombotic agents
US6391901B1 (en) 1997-04-30 2002-05-21 Eli Lilly And Company Thrombin inhibitors
US6541499B1 (en) 1997-05-01 2003-04-01 Eli Lilly And Company Antithrombotic agents
US6844358B2 (en) * 1998-05-12 2005-01-18 Wyeth Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US7056931B2 (en) 2001-05-22 2006-06-06 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7943788B2 (en) 2003-08-01 2011-05-17 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US7943582B2 (en) 2006-12-04 2011-05-17 Mitsubishi Tanabe Pharma Corporation Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US8013001B2 (en) 2001-12-21 2011-09-06 Exelixis, Inc. Modulators of LXR
US8278290B2 (en) 2005-02-14 2012-10-02 Biononics Limited Tubulin polymerisation inhibitors
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US8853385B2 (en) 2008-01-17 2014-10-07 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
US9024009B2 (en) 2007-09-10 2015-05-05 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US9174971B2 (en) 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
US10617668B2 (en) 2010-05-11 2020-04-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
US11207337B2 (en) 2015-09-15 2021-12-28 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
US11576894B2 (en) 2009-07-08 2023-02-14 Janssen Pharmaceutica Nv Combination therapy for the treatment of diabetes

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620837B1 (en) * 1999-11-19 2003-09-16 Eli Lilly And Company Antithrombotic agents
JP4656939B2 (ja) * 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
US7296361B2 (en) * 2003-07-31 2007-11-20 University Of Pittsburgh Measuring device and method of measuring
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
WO2013087647A1 (en) 2011-12-15 2013-06-20 Bayer Intellectual Property Gmbh Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
KR20170118687A (ko) 2015-02-19 2017-10-25 제이엔씨 주식회사 벤조티오펜을 가지는 액정성 화합물, 액정 조성물 및 액정 표시 소자
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001426A (en) * 1974-10-17 1977-01-04 Smithkline Corporation Substituted benzofurans and benzothiophenes
US4007204A (en) * 1974-06-06 1977-02-08 Labaz Benzothiophene compounds and the production and use thereof
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US5371091A (en) * 1992-08-31 1994-12-06 Bristol-Myers Squibb Company Heteroaromatic amine thrombin inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
WO1992008709A1 (de) 1990-11-15 1992-05-29 Pentapharm Ag Meta-substituierte phenylalanin-derivate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5523309A (en) * 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
JPH10204082A (ja) 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
US5929090A (en) 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007204A (en) * 1974-06-06 1977-02-08 Labaz Benzothiophene compounds and the production and use thereof
US4001426A (en) * 1974-10-17 1977-01-04 Smithkline Corporation Substituted benzofurans and benzothiophenes
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US5371091A (en) * 1992-08-31 1994-12-06 Bristol-Myers Squibb Company Heteroaromatic amine thrombin inhibitors

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835871A1 (en) * 1996-10-10 1998-04-15 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, formulations, and methods
US6172100B1 (en) 1997-04-30 2001-01-09 Eli Lilly And Company Antithrombotic agents
US6271227B1 (en) 1997-04-30 2001-08-07 Eli Lilly And Company Antithrombotic Agents
US6350774B1 (en) 1997-04-30 2002-02-26 Eli Lilly And Company Antithrombotic agents
US6288105B1 (en) 1997-04-30 2001-09-11 Eli Lilly And Company Antithrombotic agents
EP0980366A1 (en) * 1997-04-30 2000-02-23 Eli Lilly And Company Antithrombotic agents
WO1998048794A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
EP0980366A4 (en) * 1997-04-30 2000-05-17 Lilly Co Eli ANTITHROMOSIS
US6391901B1 (en) 1997-04-30 2002-05-21 Eli Lilly And Company Thrombin inhibitors
US6541499B1 (en) 1997-05-01 2003-04-01 Eli Lilly And Company Antithrombotic agents
US7008950B1 (en) 1997-06-05 2006-03-07 Takeda Chemical Industries, Ltd. Benzofurans as suppressors of neurodegeneration
WO1998055454A2 (en) * 1997-06-05 1998-12-10 Takeda Chemical Industries, Ltd. Benzofurans and benzothophenes as suppressors of neurodegeneration
WO1998055454A3 (en) * 1997-06-05 1999-03-04 Takeda Chemical Industries Ltd Benzofurans and benzothophenes as suppressors of neurodegeneration
US6017914A (en) * 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
US6844358B2 (en) * 1998-05-12 2005-01-18 Wyeth Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6133262A (en) * 1998-10-28 2000-10-17 Eli Lilly And Company Antithrombotic agents
EP0997460A1 (en) * 1998-10-28 2000-05-03 Eli Lilly And Company Benzothiophene compounds as antithrombotic agents and intermediates
US6359136B1 (en) 1998-10-30 2002-03-19 Eli Lilly And Company Antithrombotic agents
US6265416B1 (en) 1998-10-30 2001-07-24 Eli Lilly And Company Antithrombotic agents
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US7056931B2 (en) 2001-05-22 2006-06-06 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US8013001B2 (en) 2001-12-21 2011-09-06 Exelixis, Inc. Modulators of LXR
US7943788B2 (en) 2003-08-01 2011-05-17 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EP2896397A1 (en) 2003-08-01 2015-07-22 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
US8202984B2 (en) 2003-08-01 2012-06-19 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US8222219B2 (en) 2003-08-01 2012-07-17 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EP3251679A1 (en) 2003-08-01 2017-12-06 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
EP2514756A1 (en) 2003-08-01 2012-10-24 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US8278290B2 (en) 2005-02-14 2012-10-02 Biononics Limited Tubulin polymerisation inhibitors
US8557982B2 (en) 2005-02-14 2013-10-15 Bionomics Limited Tubulin polymerisation inhibitors
US7943582B2 (en) 2006-12-04 2011-05-17 Mitsubishi Tanabe Pharma Corporation Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
US8513202B2 (en) 2006-12-04 2013-08-20 Mitsubishi Tanabe Pharma Corporation Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
US9024009B2 (en) 2007-09-10 2015-05-05 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US8853385B2 (en) 2008-01-17 2014-10-07 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US11576894B2 (en) 2009-07-08 2023-02-14 Janssen Pharmaceutica Nv Combination therapy for the treatment of diabetes
US9174971B2 (en) 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
US10617668B2 (en) 2010-05-11 2020-04-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US11207337B2 (en) 2015-09-15 2021-12-28 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Also Published As

Publication number Publication date
ES2233982T3 (es) 2005-06-16
US6025382A (en) 2000-02-15
CA2236007A1 (en) 1997-07-17
US6251921B1 (en) 2001-06-26
EP0863755A1 (en) 1998-09-16
US6265575B1 (en) 2001-07-24
DE69634045T2 (de) 2005-05-19
AU7725596A (en) 1997-08-01
EP0863755B1 (en) 2004-12-15
ATE284690T1 (de) 2005-01-15
DE69634045D1 (de) 2005-01-20
JP2002500618A (ja) 2002-01-08
EP0863755A4 (en) 1999-01-20

Similar Documents

Publication Publication Date Title
US6251921B1 (en) Antithrombotic diamines
EP0999834B1 (en) Antithrombotic agents
EP1027051B1 (en) Antithrombotic agents
US6172100B1 (en) Antithrombotic agents
US6090843A (en) Benzothiophenes compounds which have useful pharmaceutical activity
US6350774B1 (en) Antithrombotic agents
EP0980366B1 (en) Antithrombotic agents
US6284756B1 (en) Antithrombotic agents
US6288105B1 (en) Antithrombotic agents
EP0997460B1 (en) Benzothiophene compounds as antithrombotic agents and intermediates
EP1244655B1 (en) Antithrombotic agents
WO1998048798A1 (en) Antithrombotic agents

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 836680

Date of ref document: 19970430

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2236007

Country of ref document: CA

Ref country code: CA

Ref document number: 2236007

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996940354

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996940354

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996940354

Country of ref document: EP